secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001437749-25-009351
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic FY2024: revenue $3.5M (+21%), net loss $5.8M ($0.20/shr), cash $9.3M
---------------------------------------------------------------------------

- Revenue $3.495M, up from $2.899M in 2023; driven by $1M Proliant license and $890k Inzymes success fees.
- Net loss $5.809M ($0.20 per share), improved from $6.795M ($0.24 per share) in 2023.
- Cash and investment-grade securities $9.288M at Dec 31, 2024 vs $7.273M at year-end 2023.
- Up to $7.5M in grants from CEPI (up to $2.4M for Dyadic) and Gates Foundation for C1 platform.
- Human Serum Albumin commercial launch expected Q2 2025; DNase1 advancing with EU CDMO partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774925009351/0001437749-25-009351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774925009351/dyai20240925_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-009351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer